The PARADIGM Trial
A New U.S. Medical Device Trial Assessing the Use of NeuRx® Diaphragm
Pacing System (DPS) With NIV (e.g. BiPAP, Trilogy®, etc.) In Patients With ALS.
For more information about the study or for a participating study site near
you, please contact Synapse Biomedical, Inc.
Call toll free 1.888.767.3770 or email info@synapsebiomedical.com
Only FDA device specifically approved for ALS patients
For patients with ALS, the FDA approved NeuRx DPS® delays the need for mechanical ventilation and tracheostomy. It has also been shown to help condition the diaphragm muscle to improve fatigue resistance.
Our breakthrough diaphragm pacing system for spinal cord injuries
Our FDA approved NeuRx DPS® is specifically designed to decrease the reliance on mechanical ventilators for patients with spinal cord injuries.
What NeuRx DPS® Patients Are Saying
01Nov
Use of diaphragm pacing in the management of acute cervical spinal cord injury.
Kerwin AJ1, Yorkgitis BK2, Ebler DJ2, Madbak FG3, Hsu AT4, Crandall ML2. Author information Abstract Background: Cervical spinal cord injury (CSCI) is devastating... Read More →
06Sep
Long-term experience with diaphragm pacing for traumatic spinal cord injury: Early implantation should be considered.
Onders RP1, Elmo M2, Kaplan C2, Schilz R3, Katirji B4, Tinkoff G2. Author information Abstract Background: Cervical spinal cord injury can result in.. Read More →
15Oct
Synapse Biomedical and Case Western Reserve University Announce Collaboration to Commercialize Advanced Neurostimulation Technology
With the support of a $3 million Ohio Third Frontier Innovation Platform Program grant, Synapse Biomedical Inc. will lead the commercialization of third.. Read More →